Navigation Links
Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
Date:10/30/2007

cular Medicine, University of Leeds, U.K. at the National Cancer Research Institute Cancer Conference in Birmingham, U.K.

In this study, the investigators infected melanoma cell lines with reovirus. The reovirus-infected cell lines stimulated the maturation of dendritic cells, which in turn educated cancer-killing T cells to attack and kill the melanoma cells.

Manufacturing and Process Development

We continued to have REOLYSIN(R) manufactured in order to supply our current and future clinical trial program. In the third quarter of 2007, our manufacturing activity was focused on the completion of the vial filling and packaging of the production runs that were completed earlier in 2007. Also in the third quarter of 2007, we continued process development that examined the scale up of our manufacturing process increasing the batch size from our present GMP scale of 20-litres to 40-litres and then to 100-litres.

Intellectual Property

In the third quarter of 2007, two U.S. patents were issued. At the end of the third quarter of 2007, we had been issued over 150 patents including 23 U.S. and six Canadian patents as well as issuances in other jurisdictions. We also have over 180 patent applications filed in the U.S., Canada and other jurisdictions.

Financial Impact

We estimated at the beginning of 2007 that our monthly cash usage would be approximately $1,400,000 for 2007. Our cash usage for the nine months ending September 30, 2007 was $10,849,863 from operating activities and $635,815 for the purchases of intellectual property and capital assets which is in line with our estimate. Our net loss for the nine month period ending September 30, 2007 was $11,556,714.

Cash Resources

We exited the third quarter of 2007 with cash resources totaling $28,191,464 (see "Liquidity and Capital Resources").

Expected REOLYSIN(R) Development for the Remainder of 2007

We plan to continue to enroll patients in our seven clinic
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related biology technology :

1. The state of global biotech: An Ernst & Young perspective
2. Olympics of biotechnology has international flavor
3. Biotech officials praise focus of new venture fund
4. Getting noticed in Genetown: Wisconsin biotech on display
5. Madison biotech NimbleGen files for IPO; one of states best-funded firms
6. Wisconsin biotech firm receives $107K NIH grant
7. Biotech executive books a career flight thats closer to home
8. Manufacturing partnership will move into biotech and biomedical spaces
9. Wisconsin wont get Georgia biotech without a fight
10. The 10 biggest events shaping biotech in 2006
11. Gala Biotech among companies sold for $3.3 billion
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 2Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 3Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 4Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 5Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 6Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 7Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 8Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 9Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 10Brooding fishes take up nutrients from their own children 2First-in-class treatment for acute leukemia 2First-in-class treatment for acute leukemia 3Michael J Fox Foundation Commits Up to 245 Million to Help Advance Neurotrophic Factors From Promise to Reality As Parkinsons Treatment 58205 1Michael J Fox Foundation Commits Up to 245 Million to Help Advance Neurotrophic Factors From Promise to Reality As Parkinsons Treatment 58205 2American Heart Association Meeting Report 3A High Sugar Diet Increases Mens Blood Pressure 3B Gout Drug Protective 58200 1American Heart Association Meeting Report 3A High Sugar Diet Increases Mens Blood Pressure 3B Gout Drug Protective 58200 2American Heart Association Meeting Report 3A High Sugar Diet Increases Mens Blood Pressure 3B Gout Drug Protective 58200 3American Heart Association Meeting Report 3A High Sugar Diet Increases Mens Blood Pressure 3B Gout Drug Protective 58200 4American Heart Association Meeting Report 3A High Sugar Diet Increases Mens Blood Pressure 3B Gout Drug Protective 58200 5American Heart Association Meeting Report 3A High Sugar Diet Increases Mens Blood Pressure 3B Gout Drug Protective 58200 6Abbotts XIENCE V 28R 29 Demonstrates Significantly Lower Rates of MACE and Stent Thrombosis Compared to TAXUS 28R 29 Liberte in Investigator Initiated 5042 1Abbotts XIENCE V 28R 29 Demonstrates Significantly Lower Rates of MACE and Stent Thrombosis Compared to TAXUS 28R 29 Liberte in Investigator Initiated 5042 2Abbotts XIENCE V 28R 29 Demonstrates Significantly Lower Rates of MACE and Stent Thrombosis Compared to TAXUS 28R 29 Liberte in Investigator Initiated 5042 3